Sino Biopharmaceutical (1177) Fundamentals 2026 — P/E 35.5x, Revenue Analysis | SniperIQ
Sino Biopharmaceutical (1177) is a HK-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of HK$95.3B, trading at HK$5.35 on the HKSE. This SniperIQ fundamentals page covers Sino Biopharmaceutical's valuation (P/E 35.5x, P/B 2.7x), profitability (net margin 7.4%), revenue (¥31.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sino Biopharmaceutical's market cap?
Sino Biopharmaceutical (1177) has a market capitalization of approximately HK$95.3B, trading at HK$5.35 on the HKSE. Market cap moves with the live share price.
What is Sino Biopharmaceutical's P/E ratio?
Sino Biopharmaceutical's trailing twelve-month P/E ratio is 35.5x, with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sino Biopharmaceutical?
Sino Biopharmaceutical runs a net profit margin of 7.4%, a gross margin of 82.1%, and an operating margin of 21.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sino Biopharmaceutical generate?
Sino Biopharmaceutical reported revenue of ¥31.8B for fiscal year 2025, with net income of ¥2.3B and earnings per share (EPS) of 0.13. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sino Biopharmaceutical pay a dividend?
Sino Biopharmaceutical offers a trailing dividend yield of about 1.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Sino Biopharmaceutical financially healthy?
Sino Biopharmaceutical carries a debt-to-equity ratio of 0.52x and a current ratio of 1.37x, with a market beta of 0.60. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sino Biopharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sino Biopharmaceutical (1177) the key facts are: market cap HK$95.3B, P/E 35.5x, revenue ¥31.8B, 52-week range 4.19-9.12. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sino Biopharmaceutical's full fundamentals live
Get Sino Biopharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.